Business
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential che
About this update from Exozymes Inc.
[{"type":"image","alt":"eXoZymes Inc.","displaySize":"","headline":null,"caption":"eXoZymes Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/7690e51531a13747b9ca690ce6bbbb02"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jzFu1tUAndfYNerOlwv7aw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7690e51531a13747b9ca690ce6bbbb02","width":300,"height":300}},"lazy":false},{"type":"text","content":"Expanded leadership team as eXoZymes ramps up commercial growth","length":63,"tagName":"p"},{"type":"text","content":"Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies","length":127,"tagName":"p"},{"type":"text","content":"Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners","length":113,"tagName":"p"},{"type":"text","content":"Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO).","length":331,"tagName":"p"},{"type":"text","content":"Perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Before joining eXoZymes, Perriman most recently has served leading commercial roles at both Genomatica (Geno) and Gevo, while also serving as Chairman of the Board of Danish biotechnology startup Cellugy.","length":448,"tagName":"p"},{"type":"text","content":"“eXoZymes represents the new generation of SynBio design and scale-up, setting new standards for development speed and opening a range of commercially compelling product opportunities. This new approach can overcome process titer constraints and the feedstock limitations of conventional technologies, enabling projects to reach commercial scale sooner and with lower capital risk. This sets us up to be an innovative and reliable solutions provider for companies looking to make greater imp...